Shivam Puri, CEO, Cipla Health, discusses the brand proposition of Prolyte ORS, shares strategy that helped brand achieve Rs ...

Brand-heavy companies such as Mankind Pharma, Sun Pharma, Torrent Pharmaceuticals and Eris Lifesciences are expected to ...

Cipla Ltd, a major player in the Indian pharmaceutical sector, currently trades at ₹1,418. This price reflects a decrease of ...

The company's revenue from product sales during the quarter grew by 5.6%, totaling ₹6,961 Crore, up from ₹6,589 Crore in Q2 ...

Shares of pharma major Cipla Ltd surged sharply in Thursday's trading session after the US Food and Drug Administration ...

Shares of pharmaceutical giant Cipla dipped 5 per cent at Rs 1,403 per share on the NSE in Wednesday's intraday deals: Cipla ...

How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

Cipla , India's third-largest generic drugmaker by sales, reported a 15.2% rise in second-quarter profit that beat estimates, ...

Total research and development spend reached Rs 385 crore, equivalent to 5.5 per cent of sales, a 2 per cent increase Y-o-Y.

The pharma stock is up 26 per cent year-to-date. Cipla’s ANDA filings and approvals had slowed ... we expect it to offer ...

Mumbai: Through a recent BSE filing, Cipla has informed that the United States Food and Drug Administration (USFDA) has ...

The shares of Cipla rocketed almost 10 per cent on the NSE (National Stock Exchange) after pharmaceutical titan's goa ...